Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The cumulative incidence was 6.7% for semaglutide versus 0.8% for the non-GLP-1 RA group over 36 months
Andreassen OA, Dedeoglu A, et al
The medication contains semaglutide, the same active compound found in FDA-approved obesity treatments
Nat Med (2022) 28:5918
This increase in visceral abdominal fat is linked with increased inflammation and free fatty acids that impair metabolic function, and is also linked to a higher risk of cardiovascular disease and metabolic syndrome
What matters most is improving health in a safe and sustainable way, with the right clinical guidance and support to help each person find the treatment that works best for them. James OLoan, CEO and Prescribing Pharmacist at Chemist4U The science: what the trials show Oral GLP-1 tablets are not simply traditional diet pills' in a new format
